Price (delayed)
$3
Market cap
$262.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$230.91M
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab
There are no recent dividends present for ALLK.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.